Background: Deubiquitinating enzymes (DUBs) are a critical component of the ubiquitin-proteasome system, responsible for the removal of ubiquitin from proteins. This process plays a vital role in regulating protein stability, localization, and activity. Dysregulation of the ubiquitin-proteasome system, including DUB activity, is implicated in various diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. By targeting DUBs with specific inhibitors, it is possible to modulate protein degradation pathways, offering potential therapeutic interventions for these diseases.
Detection of DUB Activity: Our DUB activity assays utilize the Fluorescence Intensity (FI) method, employing the fluorescent group Rhodamine 110. This group is conjugated to a ubiquitin molecule, and upon cleavage of ubiquitin by DUBs, the change in fluorescence is measured. Using a BMG instrument, we can accurately detect the release of the unbound fluorescent group, providing a precise reflection of DUB enzyme activity. This method allows for sensitive and reliable detection of DUB activity, making it an ideal tool for drug discovery and development.
Comprehensive DUB Assay Services: Our team has successfully developed enzymatic assays for 37 different types of DUBs, offering a wide range of services tailored to the needs of our clients. Whether you require targeting of individual DUBs or a comprehensive panel format, our assays provide the flexibility and precision needed to evaluate the efficacy of potential DUB inhibitors. These services are essential for advancing research in the ubiquitin-proteasome system and for the development of novel therapeutic strategies.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.